CTLA4 and neoplasm: CTLA-4 blockade with mAbs (i.e., ipilimumab) can then enhance the immune response against tumor by inactivating Treg, tumor-infiltrating lymphocytes (TILs) (29) and increasing T helper (Th)1 cell functions (20).